Clinical trial · no report yet · Phase 3
STAMPEDE2
A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
- NCT06320067 ↗
- Recruiting
- University College, London
- 68 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 37 | |
| Podcasts | 22 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- Studying Treatments in Patients Receiving Androgen Deprivation Therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and Radiation Efficacy: A 2nd Multi-arm Multi-stage Randomised Controlled Trial (STAMPEDE2).
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Stereotactic Ablative Body Radiotherapy (SABR); 177Lu-PSMA-617; Androgen Deprivation Therapy (ADT); Androgen Receptor Signalling Inhibitor (ARPI); Radiotherapy to Prostate ± Pelvic Nodes; Docetaxel
- Arms
- Arm A of SABR Comparison · Active comparator
- Arm S of SABR Comparison · Experimental
- Arm A of 177Lu-PSMA-617 Comparison · Active comparator
- Arm P of 177Lu-PSMA-617 Comparison · Experimental
- Enrollment
- 3,360 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- University College, London with Cancer Research UK, Novartis
- Start
- Jun 11, 2024
- Primary completion
- Apr 2031 (estimated)
- Results posted
- No
- Registry record
- NCT06320067 · updated Sep 26, 2025